Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Reaches New 12-Month High – Time to Buy?

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) reached a new 52-week high during trading on Tuesday . The company traded as high as $11.34 and last traded at $11.04, with a volume of 134744 shares changing hands. The stock had previously closed at $10.97.

Analyst Upgrades and Downgrades

Separately, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Fresenius SE & Co. KGaA in a report on Monday, February 3rd.

Fresenius SE & Co. KGaA Stock Down 0.7 %

The stock has a 50 day moving average price of $10.45 and a 200 day moving average price of $9.56. The stock has a market capitalization of $24.82 billion, a price-to-earnings ratio of 52.90 and a beta of 0.86. The company has a quick ratio of 1.05, a current ratio of 1.36 and a debt-to-equity ratio of 0.57.

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) last posted its quarterly earnings data on Wednesday, February 26th. The company reported $0.18 earnings per share for the quarter. The business had revenue of $6.01 billion during the quarter. As a group, analysts forecast that Fresenius SE & Co. KGaA will post 0.79 EPS for the current year.

Fresenius SE & Co. KGaA Company Profile

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.